Introduction Heparin is the primary anticoagulant for cardiopulmonary bypass (CPB) support
during cardiac surgery. While widely used,∼ 2% of cardiac surgery patients develop …

Objectives To determine the dosage of bivalirudin as the anticoagulant for cardiac surgery in
neonates and infants. Design Pilot study. Setting Tertiary-care hospital. Participants Twenty …

Aims: To explore the role of the Sphingosine 1-Phosphate (S1P)/Receptor2 (S1PR2)
pathway in thrombin-induced hyperpermeability (TIP) and to test whether bivalirudin can …

Introduction Bivalirudin is recommended as an alternative to heparin in cardiac surgery with
cardiopulmonary bypass. Although it has been used in infants and children for this …

Aim A typical adult‐based bivalirudin regimen during cardiopulmonary bypass uses a
loading dose of 1 mg kg− 1 and a circuit prime (volume L× 13 mg) with a subsequent …

Objectives: Bivalirudin is a direct thrombin inhibitor that is being increasingly used for
anticoagulation in children after ventricular assist device (VAD) implantation. While the data …

Anticoagulation strategies for cardiac surgery are witnessing a change with the identification
of serious limitations of heparin, including development of resistance in 3 to 13% of patients …

Various clinical scenarios may require the short or longterm administration of agents to
provide anticoagulation. In the vast majority of scenarios and clinical situations, heparin …

Zusammenfassung Hintergrund: Trotz der Seltenheit der Thrombophilie bei Neugeborenen
wird sie durch lebensbedrohliche Komplikationen zu einem der relevantesten Probleme in …

Postoperative bleeding is the most common complication after pediatric cardiac surgery. Up
to 5% of cardiac surgery will require re-exploration for significant blood loss in the first 24 h …